Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.

摘要: "Double-hit" and "double-expressor" lymphomas represent distinct but overlapping subsets of aggressive B-cell non-Hodgkin lymphoma. The high rates bone marrow involvement by these pose a major therapeutic challenge due to the chemotherapy-resistant nature microenvironment limited utility rituximab-based salvage regimens in patients with relapsed/refractory disease. Preclinical studies utilizing high-dose cyclophosphamide combination anti-CD52 monoclonal antibody alemtuzumab have recently shown promise treatment intramedullary disease, Phase I human trial is now underway. In support such efforts, here we perform CD52 target validation on series double-hit (n = 40) double-expressor 58) using immunohistochemistry. expression levels varied considerably across samples, however positive staining was observed 75% both lymphomas. Similarly, were seen whose disease associated high-risk clinical features, including primary refractory status (73%), higher IPI score (76%), (74%). not significantly correlated diagnostically relevant pathologic features as morphology, cytogenetic findings or other immunophenotypic notably present all cases lacking CD20 6). We propose that be evaluated case-by-case basis guide eligibility for enrollment.